Paper Details

  1. Home
  2. Paper Details

The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial.

Author: , BatyJack, BochicchioGrant V, BochicchioKelly, CapAndrew P, Coleoglou CentenoAdrian A, FuchsAnja, HornChristopher B, LevyJerrold H, MeledeoM Adam, PusateriAnthony E, ReeseStacey, SchuererDouglas, SheaSusan M, SpinellaPhilip C, ThomasKimberly A, TurnbullIsaiah R

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

A randomized controlled trial was conducted to investigate the immunomodulatory effects of tranexamic acid (TXA) in trauma patients with severe injury. 149 patients were randomized to receive either placebo or a 2 g or 4 g intravenous TXA bolus dose. The primary outcome was a reduction in monocyte activation, which was measured by human leukocyte antigen-DR isotype (HLA-DR) expression on monocytes 72 h after TXA administration. The study found that 4 g intravenous bolus dosing of TXA had minimal immunomodulatory effects with respect to leukocyte phenotypes and circulating cytokine levels.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The hemostatic properties of tranexamic acid (TXA) are well described, but the immunological effects of TXA administration after traumatic injury have not been thoroughly examined. We hypothesized TXA would reduce monocyte activation in bleeding trauma patients with severe injury. METHO...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506112/

データ提供：米国国立医学図書館（NLM）

Tranexamic Acid: A Versatile Tool in Trauma Management

Traumatic bleeding, like a sudden desert gash, can be a life-threatening emergency. Tranexamic acid (TXA), a medication known for its hemostatic properties, is often used to control bleeding in trauma patients, like applying a healing bandage to a desert wound. This study explores the immunological effects of TXA, investigating how it interacts with the body's immune system, like examining the intricate workings of a desert ecosystem.

The Immunological Landscape of Tranexamic Acid

The study found that high doses of TXA have minimal immunomodulatory effects in trauma patients, suggesting that it can effectively control bleeding without significantly disrupting the immune system. This is like a well-trained desert nomad, capable of quickly responding to a crisis without disturbing the delicate balance of the desert ecosystem.

A Promising Tool for Trauma Care

This research provides valuable insights into the safety and efficacy of TXA in trauma management. It's like finding a new tool in the desert nomad's toolkit, capable of effectively treating a wide range of injuries while maintaining the overall health and well-being of the patient.

Dr.Camel's Conclusion

This study offers valuable insights into the immunological effects of TXA, demonstrating its potential as a safe and effective treatment for traumatic bleeding. It's like discovering a new oasis in the desert of trauma care, providing a source of relief and hope for patients facing life-threatening injuries.

Date :
  1. Date Completed 2021-04-28
  2. Date Revised 2021-05-11
Further Info :

Pubmed ID

33013880

DOI: Digital Object Identifier

PMC7506112

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.